Behbood Sadrolhefazi
Overview
Explore the profile of Behbood Sadrolhefazi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heymach J, Opdam F, Barve M, Tu H, Wu Y, Berz D, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401727.
PMID: 40030100
Purpose: Human epidermal growth factor receptor 2 (HER2) alterations occur in many solid cancers, including non-small cell lung cancer (NSCLC). Beamion LUNG-1 (ClinicalTrials.gov identifier: NCT04886804) is assessing the safety/efficacy of...
2.
Tian X, Esmaeili H, Minich D, Seitz F, Roessner P, Wind S, et al.
Pharmacotherapy
. 2024 Dec;
45(2):94-103.
PMID: 39727284
Introduction: Zongertinib (BI 1810631) is a potent, selective, and epidermal growth factor receptor (EGFR) wild-type sparing human epidermal growth factor receptor 2 (HER2) inhibitor. Based on in vitro data, the...
3.
Schoffski P, Machiels J, Rottey S, Sadrolhefazi B, Musa H, Marzin K, et al.
Eur J Cancer
. 2023 Aug;
191:112987.
PMID: 37556913
Background: Bromodomain and extraterminal domain (BET) inhibitors have demonstrated efficacy in solid tumours and haematological malignancies. BI 894999 is a novel oral BET inhibitor that has demonstrated potent antitumour activity...
4.
Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, et al.
Clin Lung Cancer
. 2022 Dec;
24(2):e65-e68.
PMID: 36528522
Background: BI 1810631 is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. This...
5.
Hickish T, Mehta A, Liu M, Huang C, Arora R, Chang Y, et al.
Breast Cancer Res Treat
. 2022 Feb;
192(3):593-602.
PMID: 35138529
Purpose: Resistance to HER2 (ErbB2)-targeted therapy may be mediated by other members of the ErbB family. We investigated the efficacy and safety of the irreversible ErbB family blocker, afatinib, alone...
6.
Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu D, Isla D, et al.
Clin Lung Cancer
. 2019 Feb;
20(3):e407-e412.
PMID: 30808583
Background: Afatinib is a selective, irreversible ErbB family blocker that has shown survival benefit in lung squamous-cell carcinoma (SCC) patients. Pembrolizumab, a humanized immunoglobulin G4 monoclonal antibody to the programmed...
7.
Martin N, Isambert N, Gomez-Roca C, Goeldner R, Zanetta S, Sadrolhefazi B, et al.
Cancer Chemother Pharmacol
. 2018 Oct;
82(6):979-986.
PMID: 30350178
Background: Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in...
8.
Ellis P, Leighl N, Hirsh V, Reaume M, Blais N, Wierzbicki R, et al.
Clin Lung Cancer
. 2015 Jun;
16(6):457-65.
PMID: 26100229
Unlabelled: Second-line therapy options that improve survival for patients with advanced non-small-cell lung cancer (NSCLC) are needed. This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in...
9.
Saatee S, Afrakhteh M, Sadrolhefazi B
Breast J
. 2006 Sep;
12(5):499-501.
PMID: 16958978
No abstract available.